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Abstract 
Background: The Sars-CoV-2 can cause severe pneumonia with multiorgan disease; thus, the identification of clinical 
and laboratory predictors of the progression towards severe and fatal forms of this illness is needed. Here, we retro-
spectively evaluated and integrated laboratory parameters of 45 elderly subjects from a long-term care facility with 
Sars-CoV-2 outbreak and spread, to identify potential common patterns of systemic response able to better stratify 
patients’ clinical course and outcome.
Methods: Baseline white blood cells, granulocytes’, lymphocytes’, and platelets’ counts, hemoglobin, total iron, 
ferritin, D-dimer, and interleukin-6 concentration were used to generate a principal component analysis. Statistical 
analysis was performed by using R statistical package version 4.0.
Results: We identified 3 laboratory patterns of response, renamed as low-risk, intermediate-risk, and high-risk, 
strongly associated with patients’ survival (p < 0.01). D-dimer, iron status, lymphocyte/monocyte count represented 
the main markers discriminating high- and low-risk groups. Patients belonging to the high-risk group presented a 
significantly longer time to ferritin decrease (p: 0.047). Iron-to-ferritin-ratio (IFR) significantly segregated recovered and 
dead patients in the intermediate-risk group (p: 0.012).
Conclusions: Our data suggest that a combination of few laboratory parameters, i.e. iron status, D-dimer and lym-
phocyte/monocyte count at admission and during the hospital stay, can predict clinical progression in COVID-19.
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Background
Severe acute respiratory syndrome coronavirus 2 (Sars-
CoV-2), the viral agent causing the novel coronavirus 
disease 2019 (COVID-19), has generated an ongoing 
worldwide pandemic after its initial outbreak in Wuhan, 
China [1, 2].
Diagnosis of COVID-19 is typically performed using 
polymerase chain reaction testing via nasopharyngeal 
swab. However, because of the false-negative test result 
rates of Sars-CoV-2 PCR testing by nasopharyngeal 
swabs, several clinical, laboratory, and imaging findings 
have been useful to make a presumptive diagnosis [3, 4]. 
Sars-CoV-2 infection may be asymptomatic, or it may 
cause a wide spectrum of symptoms, such as fever, dry 
cough, and shortness of breath. COVID-19 severity can 
also progress to severe and eventually critical conditions 
defined by respiratory failure, septic shock, and/or multi-
ple organ dysfunction [5–9]. It is therefore of paramount 
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of the progression of this illness for timely clinical/thera-
peutic decision-making. Common laboratory abnormali-
ties among hospitalized patients include lymphopenia 
(83%), elevated inflammatory markers (eg., erythrocyte 
sedimentation rate, C-reactive protein, ferritin, tumor 
necrosis factor-α, IL-1, IL-6), and abnormal coagulation 
parameters (eg., prolonged prothrombin time, throm-
bocytopenia, elevated D-dimer, low fibrinogen). Most 
of these laboratory characteristics are nonspecific and 
are common in pneumonia. Aside from the established 
clinical risk factors, lymphopenia (absolute lymphocyte 
count < 1.0 × 109/L) is the sole cardinal laboratory finding 
with prognostic potential [1, 10–13]. Furthermore, differ-
ent acute phase biomarkers, like ferritin, and a hyperco-
agulability state, indicated by elevated D-dimer, have all 
been associated with greater illness severity and mortal-
ity [12, 13].
In the present study, we retrospectively evaluated and 
integrated laboratory parameters/variables of 45 COVID-
19 patients admitted to our hospital, consisting of a 
homogenous group of elderly subjects from a long-term 
care facility with Sars-CoV-2 outbreak and spread, to 
identify potential common patterns of systemic response 
able to better stratify patients’ clinical course and out-
come, independently from clinical co-morbidities.
Methods
All methods were carried out in accordance with relevant 
guidelines and regulations.
Patients
This study was carried out at the ‘COVID unit’ of the 
Magna Graecia University—“Mater Domini” Hospital in 
Catanzaro, Italy from March 9th to April 1st, 2020. The 
study was approved by the Magna Graecia University 
institutional ethics committee, and a waiver of informed 
consent was obtained by the committee.
All patients included in this case series had a Sars-
Cov-2 laboratory-confirmed infection diagnosed by 
quantitative reverse transcriptase-PCR (qRT-PCR) (Gen-
eFinderTM COVID-19 Plus RealAmp Kit, Elitech Group) 
performed on nasopharyngeal specimens or bronchoal-
veolar lavage (BAL).
Clinical and laboratory assessment
Basic information such as gender, age, clinical symp-
toms, and signs was collected from the admission 
records. Admission testing included in the integrated 
analysis were hematologic parameters (i.e. white blood 
count (WBC), granulocyte count, lymphocyte count, 
monocyte count, platelets count, neutrophil-to-lym-
phocyte ratio (NLR), monocyte-to-lymphocyte ratio 
(MLR) platelet-to-lymphocyte ratio (PLR), hemoglobin 
(HGB), and iron) and inflammatory markers (i.e. ferritin, 
IL-6, and D-dimer) which were repeated along with the 
hospitalization.
Statistical analysis
Statistical analysis was performed by using R statisti-
cal package version 4.0 [14]. Specifically, laboratory data 
known to be associated with inflammation and routinely 
performed in COVID-19 patients (white blood cells, neu-
trophils, lymphocytes, platelets counts, hemoglobin, fer-
ritin, iron, D-dimer, and IL-6) were scaled to be used for 
PCA estimation. On these results, patients were clustered 
into 3 groups according to the K-means algorithm. Next, 
Student’s t-test and ANOVA (according to the number of 
groups to be tested) were used to evaluate differences in 
the means of the different variables. Pearson’s Chi-Square 
was used for comparisons between categorical variables. 
Correlation between variables was assessed by Pearson’s 
correlation test. Kaplan–Meier estimate and logrank tests 
were used for time to events (ferritin, D-dimer, and IL-6 
decrease) calculation. The following packages have been 
used during the whole analysis: base package to perform 
Student’s t-test, ANOVA and Pearson’s tests; ggpubr and 
ggplot2, for figure preparation; corrplot and corrr for 
correlation analysis; survminer for Kaplan Meier and 
logrank tests; cluster and ggfortify for PCA calculation 
and K-means based clustering, ggradar for radar plot.
Results
Patients’ characteristics at baseline
Fifty patients were admitted to our institution follow-
ing a COVID-19 outbreak that occurred in a long-term 
care facility. Of them, 45 patients with positive PCR Sars-
Cov-2 laboratory-confirmed infection, presented all the 
required laboratory variables at baseline and further pre-
sented D-dimer, IL-6, and ferritin during the follow-up; 
thus, they were included in this retrospective analysis. 
Complete clinical data together with relative therapy have 
been recently published by Trecarichi et al. [15]. Patients’ 
characteristics at baseline are reported in Table 1.
Briefly, 19 males and 26 females with a median age of 
81  years (range 55–98  years) and a median time from 
symptoms appearance to admission to hospital of 5 days 
were included in our analysis. Among them, 33 (73%) 
were under treatment for hypertension, 23 (51%) pre-
sented neurological diseases, 19 (43%) had a chronic kid-
ney failure and 11 (24%) assumed drugs for psychiatric 
disorders. The overall mortality rate was 26.67%, in line 
with that reported according to the median age of Italy 
[16].
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Laboratory pattern of response to Sars‑CoV‑2 infection
We used baseline values of blood cell count and several 
biochemical and coagulation-related parameters, widely 
used for COVID-19 patient assessment to investigate 
the occurrence of a specific pattern of response. To this 
aim, we took advantage of a dimensionality reduction 
approach, the PCA, which by segregating each patient 
according to their whole laboratory profile (the more 
similar are the profiles, the closer they are on the graph) 
allowed us to identify potential subgroups (which could 
be subsequently identified through k-means approach). 
Specifically, white blood cells, granulocytes, lympho-
cytes, and platelets count, hemoglobin, total iron, ferri-
tin, D-dimer, and interleukin 6 concentration were used 
to automatically generate a PCA and to cluster patients 
into 3 different and well-separated groups (Fig. 1a). The 
3 clusters were found to be strongly associated with 
patients’ survival (Chi-squared test p < 0.001) and were 
thus renamed as low risk (1 death over 17 patients), inter-
mediate-risk (4 deaths over 21 patients) and high risk 
(7 deaths over 7 patients) (patients distribution accord-
ing to age and sex are reported in Fig. 1b). As shown in 
Fig. 1c, 6 out of 9 variables significantly discriminated the 
3 groups, with D-dimer, lymphocytes/monocytes count, 
and iron status representing the main markers of the 
high- and low-risk group, respectively. Within the inter-
mediate-risk group we registered 4 deaths, which led us 
to hypothesize that the clustering algorithm presents a 
reduced sensitivity for “borderline” patients. Indeed, we 
assume that that in this group the presence of a “smold-
ering” systemic inflammation could have been hidden 
by other confounding factors such as iron deficiency 
anemia, which by reducing the values of serum ferritin 
impairs its potential use as inflammatory marker, or iron 
supplementation, which could lead to the opposite phe-
nomenon. To this end, we evaluated the difference in iron 
to ferritin ratio (IFR) as a surrogate marker of inflamma-
tion. Indeed, the increase of ferritin uncoupled from an 
iron increase (or in the presence of low iron values) leads 
to low IFR values and is usually associated with chronic 
inflammation [15, 16]. Of note, we observed that the dif-
ference in IFR significantly segregates recovered and dead 
patients (high IFR better prognosis) in the intermediate-
risk group (p: 0.012) (Fig. 1d).
Time to ferritin decrease correlates with patients’ survival
In the attempt to identify informative markers useful for 
monitoring illness severity and mortality, we investigated 
the modulation of ferritin serum concentration during 
hospitalization. Interestingly, we observed a quick ferri-
tin increase followed by a decalage phase almost exclu-
sively in recovering patients, which indeed presented a 
significantly short time to ferritin decrease (intended as 
the time from hospital admission to first and stable fer-
ritin decrease during hospitalization) (Fig. 2a). This trend 
was not observed neither for D-dimer nor for IL-6 con-
centration along hospitalization (Fig. 2b, c). Accordingly, 
patients belonging to the high-risk group presented a 
significantly longer time to ferritin decrease (Fig.  2d, p: 
0.047).
Correlation analyses identify lympho/monocytes count, 
D‑dimer, and iron status as “litmus paper” of the systemic 
response to SARS‑CoV‑2 infection
Lastly, we performed a correlation analysis, including 
derivative variables known to be associated with systemic 
inflammation, such as neutrophils, monocytes, and plate-
lets to lymphocytes ratio (NLR, MLR, and PLR respec-
tively). Interestingly, as shown in Fig.  3a, we observed 
the presence of three different clusters of correlated vari-
ables, which have been grouped accordingly to the main 
systemic function/role they are involved in. Among the 
different correlations observed, lymphocytes and mono-
cytes experienced a similar modulation, possibly depend-
ent on the mechanism of action of the virus. This strong 
relationship has been observed independently of the risk 
group (Fig. 3b). Moreover, we observed a direct correla-
tion between IFR and IL-6 only in the intermediate risk 
group, further underscoring the role of IFR in discrimi-
nating “hidden” inflammatory responses (Fig. 3c). Other 
potential associations between laboratory variables and 
Sex, Age, risk groups, and recovery/death have been 
Table 1 Demographic and clinical patients’ characteristics 
at baseline
Type 2 DM Type 2 Diabetes Mellitus, COPD Chronic Obstructive Pulmonary 
Disease, CKD chronic kidney disease
Patients (n = 45)
Age, years (median and range) 81 (55–98)
Sex
 Male 19 (42%)
 Female 26 (58%)
Comorbidities
 Hypertension 33 (73%)
 Type 2 DM 9 (20%)
 Malignancy 7 (16%)
 COPD 7 (16%)
 CKD 19 (42%)
 Obesity 5 (11%)
 Neurological dis 23 (51%)
 Psychiatric dis 11 (24%)
Outcome
 Recovered 33 (73%)
 Deaths 12 (27%)
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explored and reported in Additional file  1: Figures  S1–
S4. Briefly, we observed, among others, a direct correla-
tion between the amount of IL-6 and D-dimer which is 
statistically significant in female patients only, a strong 
association between monocyte and lymphocyte counts 
(which is independent from all other confounding vari-
ables and that could represent a sign of mononucleated 
cells extravasation), an inverse correlation between IFR 
and ferritin and a direct correlation between neutrophil 
count and IL-6 concentration in patients who recovered 
from lung disease (which could represent a normal con-
trol and functionality of the iron and IL-6 homeostasis).
Altogether, these results further underscore the rel-
evant role of these markers in identifying critical patients 
who potentially could benefit from increased monitoring 
and early intervention.
Comorbidities are associated with the presence of markers 
of the high‑risk group at baseline
To investigate if the presence of previous comorbidities 
is associated with changes in baseline levels of inflam-
matory variables (thus potentially affecting patients’ 
outcome), we performed a multiple t-test, evaluating 
every single variable for the association to each con-
dition.Results are reported in Fig.  4a, b as radarplot 
evaluating the impact of neurological and/or psychi-
atric disorders, cardiovascular-metabolic disease and 
of a miscellaneous group which includes malignan-
cies, chronic lung disease and chronic kidney disease. 
Among others, the presence of a concomitant malig-
nancy is associated with high levels of ferritin and low 
levels of IFR, and, in line with other reports [17] cor-
relates with a worse survival (Fig. 4c, Additional file 1: 
Table S1, p: 0.047). Interestingly, we observed that the 
presence of hypertension correlates with a worse out-





Fig. 1 Baseline laboratory parameters define different patterns of response to Sars-CoV-2 infection. a Clustering analysis by a principal component 
analysis (PCA) scatter plot. Colours and shapes respectively represent the 3 risk groups and the status of the patient (recovered or dead). b 
distribution of patients according to risk group and age or sex. c ANOVA and T-test results of the 6 parameters which mainly influenced patients’ 
clustering, according to their distribution across risk groups. Within each sub-panel, p values for ANOVA comparison (bottom) and for each pairwise 
comparison (top) are reported. d Patient distribution according to risk groups and dead/recovered status; on the right side, the histogram shows 
the comparison of iron to ferritin ratio (IFR) between recovered and dead patients within the intermediate-risk group
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change in laboratory parameters (Fig.  4b, Additional 
file 1: Table S1, p: 0.033).
Discussion
COVID-19 is associated with a high disease burden with 
nearly 20% of confirmed cases progressing towards criti-
cal illness [18]. The mortality rate in people infected with 
Sars-Cov-2 increases steeply with age, and fatal outcomes 
are almost exclusively seen in people older than 50 years 
[19]. Among the latter, the elderly in long-term care facil-
ities (LTCFs) have been reported as high vulnerable to 
infections and at high risk for mortality. NFurthermore, 
patients with severe illness are likely to suffer substan-
tial sequelae associated with a new physical disability, 
new cognitive impairment, and increased vulnerability to 
recurrent infection [14, 20, 21].
Currently, many drugs have been adopted worldwide 
for the treatment of Sars-Cov-2 pneumonia [22–27]; 
Fig. 2 Patients with a worse outcome present a significantly longer time to ferritin decrease. a–c Kaplan Meier curves reporting the time to ferritin, 
D-dimer and IL-6 decrease (intended as the time from hospital admission to first and stable decrease during hospitalization) respectively, stratified 
on dead/recovered status (p value calculated through LogRank test). d Kaplan Meier curves reporting the time to ferritin decrease stratified on risk 
groups (p value calculated through LogRank test comparing High-Risk vs. Low-Risk patients)
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however, most of these drugs failed to demonstrate 
a clear clinical benefit. It is therefore of paramount 
importance to properly identify patients who are likely 
to develop critical illness for a timely pharmaco-inva-
sive management while optimizing the use of limited 
resources.
In this study, we retrospectively evaluated and inte-
grated laboratory parameters/variables of a homogene-
ous cohort of 45 elderly subjects from a long-term care 
facility with COVID-19, to identify potential prognos-
tic factors able to better stratify patients’ clinical course 
and outcome. Radiographic and laboratory abnormali-
ties, such as lymphopenia and elevated lactate dehydro-
genase, are known to be common, but on their own are 
not specific for the diagnosis or the prognosis [1]. In 
line with previous findings, we observed that low lym-
phocytes/monocytes count as well as the high level of 
D-dimer in the peripheral blood significantly define a 
group of patients with a shattering outcome (practically 
100% mortality rate). The integration of these three lab-
oratory abnormalities well describes the known course 
and relative pathophysiology of COVID-19 [1, 10–13]. 
Indeed, profound lymphopenia occurs in individuals with 
COVID-19 when SARS-CoV-2 infects and kills T lym-
phocyte cells. The viral inflammatory response, consist-
ing of both the innate and the adaptive immune response, 
impairs lymphopoiesis, and increases lymphocyte apop-
tosis. In the progression of the viral infection, when viral 
Fig. 3 Correlations among lymph/monocytes count, D-dimer, and iron status affect the systemic response to SARS-CoV-2 infection. a Left: 
correlation plot of all variables [including derivative variables such as iron to ferritin ratio (IFR), neutrophils to lymphocytes ratio (NLR), platelets to 
lymphocytes ratio (PLR), monocytes to lymphocytes ratio (MLR)] to identify potential inter-variables correlations. The colour represents the direction 
of the correlation. Only boxes showing a significant correlation have been coloured; right, network plot showing direction and distribution of 
correlations between variables. Clusters of variables belonging to similar functions have been grouped. b Scatter plot representing the correlation 
between lymphocytes and monocytes. Remarkably, almost all the deaths are localized within the lower left quadrant of the plot. c Scatter plot 
showing the association between IL-6 and IFR. This correlation reaches statistical significance within the intermediate group only, further supporting 
the discriminating role of IFR within this subgroup
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replication accelerates, epithelial-endothelial barrier 
integrity is compromised, exacerbating the inflammatory 
response. Finally, in severe COVID-19, fulminant activa-
tion of coagulation and consumption of clotting factors 
occur [28, 29].
Importantly, our results show that the systemic iron 
metabolism associated parameters, i.e. iron status, fer-
ritin, and IFR, can help to better predict unfavorable 
outcomes and to monitor illness progression/regres-
sion in COVID-19 patients. Ferritin is a key mediator of 
immune dysregulation, especially under extreme hyper-
ferritinemia, via direct immune-suppressive and pro-
inflammatory effects, contributing to the cytokine storm. 
Previous laboratory findings highlighted that a consistent 
percentage of patients with elevated serum ferritin levels 
faced a higher probability to experience serious compli-
cations from COVID-19 [30, 31]. Accordingly, ferropto-
sis, a novel programmed cell death, has been suggested 
as an important cause of multiple organ involvement in 
COVID-19 and it might serve as a new treatment target 
[32–36].
In this study, we suggest a putative predictive value 
of the iron metabolism status as a marker of inflamma-
tion which potentially offers a new parameter to better 
stratify hospitalized patients—indeed, the increase of 
ferritin accompanied by low iron values, which result 
in elevated IFR, significantly segregates recovered and 








Fig. 4 Association between comorbidities and baseline levels of laboratory variables. a Distribution of different laboratory values according to 
baseline comorbidities: left, radar-plot showing the p values of the t-test comparing each laboratory variable with each comorbidity. The distance 
from the center correlates with the significance of the test (the more is far the more is significant); right, box plot representing the distribution 
of only the significant variables in patients presenting with (1) or without (0) comorbidities. b Radar-plot reporting CVD (cardiovascular disease) 
associated variables: none of them presents a significantly different distribution of laboratory variables. c Distribution of COVID-19-associated deaths 
according to the presence or absence of malignancies at baseline
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COVID-19 patients belonging to the so-called inter-
mediate-risk group (4 deaths over 21 patients). Our 
hypothesis is that in this group, which represents the 
largest group, the early evaluation of IFR may func-
tion as a surrogate marker able to highlight the pres-
ence of a “smoldering” systemic inflammation, which 
could have been hidden by other confounding fac-
tors. In agreement, we observed a direct correlation 
between IFR and IL-6 only in the intermediate risk 
group. Furthermore, we found that the kinetic changes 
of ferritin levels, but not those of D-dimer and IL-6, 
correlate with COVID-19 progression. Indeed, we 
observed that almost exclusively in the recovering 
patients, the ferritin concentration peak at the time of 
hospital admission is followed by a gradual decrease 
during the second and the third week of the disease 
course. Accordingly, patients belonging to the high-
risk group presented a significantly longer time to fer-
ritin decrease.
Given the relevance of the COVID-19 pandemic 
and the lack of definitive early prognostic markers, we 
believe that any contribution which advances this field 
is highly valuable. Indeed, one of the major problems 
to evaluate the clinical status of COVID-19 patients at 
admission is the still simplistic stratification into mild, 
moderate and severe forms according to respiratory 
sign/symptoms and need for oxygen therapy and/or 
mechanical ventilation. The results of the present study 
suggest that the proposed laboratory findings could 
better and preventively stratify the patients in advance 
to the development of the clinical manifestations with 
a poor prognosis. It would be of interest to re-evaluate 
patients included in published clinical trials according 
to the suggested laboratory patterns of described here 
in order to assess whether these patterns better predict 
mortality of COVID-19 patients with mild, moderate 
and severe clinical presentation and whether these lab-
oratory parameters better predict response to recom-
mended therapies such as dexamethasone, remdesivir 
and heparin and monoclonal antibodies as well [37, 38].
This study has several limitations. First, the main 
weakness of the present study is the small sample size, 
which makes the reported findings hypothesis-generat-
ing. Second, this study included elderly patients from 
a unique long-term care facility, which represents an 
isolated outbreak in a rather homogenous population 
at risk that may not be representative of the overall 
heterogeneous general COVID-19 population. Testing 
a consecutive group of random COVID-19 patients, 
both retroactively and prospectively, will surely help 
to assess whether the conclusions reached from such a 
‘population isolate’ will have general predictive value. 
Yet, it worth noting here that this study may have 
helped in generating robust evidence avoiding the con-
founding effects of multiple co-morbidities as in the 
general population.
Conclusions
The main findings of this study generate the hypothesis 
that a combination of few laboratory parameters, and in 
particular iron status, D-dimer and lymphocyte count 
can better and preventively stratify COVID-19 patients 
with a poor prognosis in advance to the development of 
the clinical manifestations. Despite the inherent value 
of the present data for this population, its wide appli-
cability to all COVID-19 patients requires validations 
in larger study cohorts, such as in patients included in 
clinical trials. This would allow to assess whether the 
proposed laboratory patterns better predict mortality 
of COVID-19 patients with mild, moderate and severe 
clinical presentation as well as the response to recom-
mended therapies.
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